ロード中...
Cell-based Immunotherapy Against Gliomas: From Bench to Bedside
Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18–21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival rate i...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3702108/ https://ncbi.nlm.nih.gov/pubmed/23648695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2013.80 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|